Haemoptysis

Quick Reference

Critical Alerts

• Massive haemoptysis is a medical emergency: Death occurs from asphyxiation, not exsanguination, as 150-200 mL of blood can fill the entire tracheobronchial tree [1]
• Bleeding side identification is critical: Position patient bleeding-side down to protect the contralateral lung from aspiration [2]
• Airway protection is paramount: Early intubation (large ETT ≥8.0 mm) if massive or compromised airway to enable bronchoscopic intervention [1,2]
• Most common cause globally: Tuberculosis remains the leading cause worldwide, particularly in endemic regions [3]
• Most common cause in developed countries: Bronchitis (acute and chronic), bronchiectasis, and lung cancer account for 60-70% of cases [4,5]
• 90% of massive haemoptysis originates from bronchial arteries: High-pressure systemic circulation, making bronchial artery embolization the intervention of choice [6,7]

Key Diagnostics

Emergency Treatment Pathway

---

Definition and Classification

Overview

Haemoptysis is the expectoration of blood originating from the lower respiratory tract (below the glottis), ranging from blood-streaked sputum to life-threatening hemorrhage. The fundamental principle of management is that death occurs from asphyxiation, not exsanguination, as relatively small volumes (150-200 mL) can completely occlude the tracheobronchial tree, preventing gas exchange and leading to hypoxic cardiac arrest. [1] The immediate priorities are securing the airway, preventing aspiration to the contralateral lung, and achieving source control.

Classification by Volume

The definition of "massive" haemoptysis varies in the literature, with thresholds ranging from 200-1000 mL per 24 hours. [1,2] However, volume-based definitions are problematic as they are difficult to quantify accurately in clinical practice, and patients with smaller volumes can deteriorate rapidly based on comorbidities and rate of bleeding.

Functional Classification (Preferred)

Modern consensus favors a functional classification over purely volumetric criteria: [2,5]

Non-Massive Haemoptysis:

• Hemodynamically stable
• Able to clear secretions spontaneously
• No respiratory compromise (SpO₂ > 90% on room air)
• No signs of ongoing massive bleeding

Massive/Life-Threatening Haemoptysis:

• Hemodynamic instability (SBP less than 90 mmHg, HR > 120 bpm)
• Respiratory distress or failure (SpO₂ less than 90% despite O₂, RR > 30)
• Inability to clear secretions
• Risk of asphyxiation (witnessed large-volume expectoration)
• Rapidly declining hemoglobin (> 2 g/dL in 24h)

This functional approach better identifies patients requiring emergency intervention regardless of absolute volume. [2]

---

Epidemiology

Incidence and Prevalence

• General population: Haemoptysis accounts for 1-4% of pulmonary medicine consultations and 6.8-15% of respiratory outpatient referrals [4,5]
• Massive haemoptysis: Represents 5-15% of all haemoptysis presentations [1,12]
• Hospital admissions: Approximately 5 per 100,000 population annually in developed countries [4]
• Emergency department presentations: 0.1-0.2% of all ED visits involve haemoptysis [5]

Mortality

• Massive haemoptysis (untreated): 30-50% mortality [1,12]
• Massive haemoptysis (with intervention): 5-20% mortality depending on underlying etiology [12]
• Non-massive haemoptysis: less than 5% mortality [4]
• Worst prognosis: Malignancy (40-50%), aspergilloma (25-30%), tuberculosis with Rasmussen aneurysm (50-80%) [3,11]

Geographic and Demographic Variation

• Developing countries: Tuberculosis is the leading cause (30-70%), followed by bronchiectasis [3]
• Developed countries: Bronchitis (25-40%), bronchiectasis (20-30%), lung cancer (15-25%) [4,5]
• Age distribution:
  • less than 40 years: Infection (bronchitis, TB), bronchiectasis, congenital lesions (AVM)
  • 40-60 years: Malignancy, chronic lung disease, TB reactivation

  • 60 years: Malignancy, bronchiectasis, cardiovascular causes

• Gender: Slight male predominance (60%) due to higher smoking rates and occupational exposures [4]

---

Etiology

Causes by Frequency (Developed Countries)

Causes by Mechanism

Airway Disease:

• Acute/chronic bronchitis: Mucosal inflammation, superficial vessel erosion
• Bronchogenic carcinoma: Tumor neovascularization, friable vessels, vascular invasion
• Bronchiectasis: Chronic inflammation → bronchial artery hypertrophy and tortuosity
• Foreign body: Direct mucosal trauma, secondary infection

Parenchymal Disease:

• Pneumonia: Necrotizing infection, abscess formation (S. aureus, K. pneumoniae, anaerobes)
• Tuberculosis: Caseous necrosis, Rasmussen aneurysm (erosion into pulmonary artery), residual cavitary disease
• Fungal infection: Aspergilloma (mycetoma), invasive aspergillosis, mucormycosis
• Lung abscess: Erosion into pulmonary vessels
• Vasculitis: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis, Goodpasture syndrome, Behçet disease, SLE
• Diffuse alveolar hemorrhage: Anti-GBM disease, drug-induced, autoimmune

Vascular Causes:

• Pulmonary embolism: Pulmonary infarction, alveolar hemorrhage (20-30% of PE) [15]
• Arteriovenous malformation (AVM): Hereditary hemorrhagic telangiectasia (HHT), isolated AVM
• Dieulafoy lesion: Ectatic bronchial artery in submucosa, prone to spontaneous rupture
• Pulmonary artery aneurysm: Rasmussen (TB), Behçet disease, chronic pulmonary hypertension
• Bronchial artery aneurysm: Chronic inflammation, atherosclerosis

Cardiovascular:

• Mitral stenosis: Elevated left atrial pressure → pulmonary venous hypertension → alveolar hemorrhage
• Left ventricular failure: Pulmonary edema with hemoptysis (pink frothy sputum)
• Aorto-bronchial fistula: Thoracic aortic aneurysm erosion; sentinel bleed followed by massive hemorrhage

Iatrogenic:

• Bronchoscopy with biopsy: Risk 0.1-5% depending on technique
• Pulmonary artery catheter: Swan-Ganz catheter erosion or rupture (1-2%)
• Anticoagulation: Unmasking underlying lesion or causing diffuse hemorrhage

Coagulopathy:

• Medication: Warfarin, DOACs, antiplatelet agents, thrombolytics
• Congenital: Von Willebrand disease, hemophilia
• Acquired: Liver disease, DIC, thrombocytopenia

Other:

• Trauma: Blunt chest trauma, penetrating injury, lung contusion
• Cocaine inhalation: Vasoconstriction → ischemia → alveolar hemorrhage
• Catamenial haemoptysis: Thoracic endometriosis (menses-related)
• Radiation-induced: Post-radiotherapy bronchial stenosis and necrosis

---

Pathophysiology

Vascular Anatomy of the Lung

The lungs receive blood supply from two distinct vascular systems with fundamentally different pressures and roles in haemoptysis: [6,7]

Bronchial Artery Anatomy:

• Typically 1-2 right bronchial arteries and 1 left bronchial artery
• Highly variable anatomy (normal variant in 70% of patients) [7]
• Supply extends to level of terminal bronchioles
• Anastomoses with pulmonary circulation at capillary level
• Hypertrophy and neovascularization occur in chronic inflammatory states (bronchiectasis, TB, chronic infection)
• Target for bronchial artery embolization (BAE)

Why Bronchial Arteries Bleed More:

1. Systemic pressure: 5-10 times higher than pulmonary circulation
2. Chronic inflammation: Leads to vessel hypertrophy, tortuosity, and fragility
3. Proximity to airways: Direct erosion from tumors, infection, foreign bodies
4. Neovascularization: Tumor-induced angiogenesis creates friable vessels

Mechanisms of Bleeding by Etiology

Bronchitis:

• Viral or bacterial infection → mucosal inflammation and hyperemia
• Superficial mucosal vessel erosion
• Increased mucosal permeability
• Usually self-limiting as inflammation resolves

Bronchiectasis:

• Chronic cycles of infection and inflammation
• Bronchial artery hypertrophy and proliferation
• Formation of tortuous, friable vessels
• Vessel erosion during acute exacerbations
• Recurrent haemoptysis common (30-50%) [13]

Tuberculosis:

• Active TB: Caseous necrosis, granulomatous inflammation, direct vessel erosion
• Rasmussen aneurysm: Mycobacterial erosion into pulmonary artery adjacent to cavity wall (pulmonary artery source, not bronchial) [3]
• Post-TB sequelae: Residual cavities colonized by Aspergillus → mycetoma
• Reactivation: Vessel erosion in apical fibrocavitary disease

Lung Cancer:

• Tumor neovascularization with immature, friable vessels
• Direct invasion and erosion of bronchial arteries
• Central endobronchial tumors (squamous cell) more prone to bleeding
• Post-obstructive pneumonia causing secondary hemorrhage
• Radiation/chemotherapy-induced necrosis

Pulmonary Embolism:

• Pulmonary infarction → alveolar hemorrhage
• Occurs in 20-30% of PE, usually small volume [15]
• Mechanism: Ischemic necrosis of lung parenchyma
• Hemorrhage from low-pressure pulmonary circulation

Aspergilloma (Mycetoma):

• Fungal ball within pre-existing cavity (TB, sarcoidosis)
• Mechanical friction → vessel erosion
• Proteolytic enzymes and toxins damage vessel walls
• Risk of massive hemorrhage: 5-25% [11]
• High mortality if bleeding occurs (25-30%)

Vasculitis (GPA, Goodpasture):

• Immune-mediated necrotizing vasculitis
• Alveolar capillaritis → diffuse alveolar hemorrhage (DAH)
• Pulmonary-renal syndrome
• Usually low-to-moderate volume, rarely massive

Why Massive Haemoptysis Kills

Asphyxiation, Not Exsanguination: [1,2]

• Total tracheobronchial tree volume: approximately 150-200 mL
• Blood fills airways → prevents gas exchange
• Hypoxia develops rapidly (minutes)
• Cardiac arrest from hypoxemia
• Death can occur with loss of less than 500 mL blood (non-lethal by exsanguination)

Protective Reflexes Overwhelmed:

• Cough reflex cannot clear large-volume hemorrhage
• Blood clots obstruct airways
• Bilateral aspiration if patient supine

Contralateral Lung Flooding:

• Blood from bleeding lung spills into contralateral lung
• Loss of functional alveolar surface area
• Shunt physiology, refractory hypoxemia

---

Clinical Presentation

History

Characterize the Bleeding:

• Onset and duration: Sudden vs. gradual; acute vs. chronic recurrent
• Volume estimation: Teaspoons, tablespoons, cups, toilet bowl estimation (notoriously inaccurate)
• Frequency: Single episode vs. multiple over days
• Color: Bright red (fresh arterial) vs. dark red/brown (older blood)
• Character: Pure blood vs. blood-streaked sputum vs. clots
• Frothy appearance: Suggests alveolar origin (pulmonary edema, DAH)
• Associated with coughing: True haemoptysis vs. vomiting (hematemesis)

Associated Symptoms:

• Fever, productive cough, dyspnea: Pneumonia, TB, lung abscess
• Weight loss, anorexia, night sweats: Tuberculosis, malignancy
• Pleuritic chest pain, sudden dyspnea: Pulmonary embolism, pneumothorax
• Chronic productive cough: Bronchiectasis, chronic bronchitis, COPD
• Sinusitis, hemoptysis, hematuria: GPA (Wegener's)
• Hemoptysis with menses: Catamenial (thoracic endometriosis)
• Dyspnea on exertion, orthopnea: Mitral stenosis, heart failure

Patient Localization:

• "Which side do you feel the bleeding is coming from?" (correct in 60-70%)
• Gurgling or bubbling sensation in one side of chest
• Unilateral chest discomfort or pain

Risk Factors and Comorbidities:

• Smoking history: Pack-years (lung cancer, COPD, chronic bronchitis)
• TB exposure or prior TB: Endemic travel, prior treatment, BCG vaccination
• Chronic lung disease: Bronchiectasis, cystic fibrosis, COPD
• Immunosuppression: HIV, transplant, chemotherapy (fungal infections)
• Cardiac history: Mitral stenosis, heart failure
• Anticoagulation: Warfarin, DOACs, antiplatelets
• Recent procedures: Bronchoscopy, transbronchial biopsy, central line placement
• Travel history: Endemic TB, parasitic infections (paragonimiasis)
• Occupational exposures: Asbestos, silica

Physical Examination

Vital Signs:

Airway and Respiratory Assessment:

Clubbing:

• Bronchiectasis, lung cancer, interstitial lung disease, cyanotic heart disease, CF

Lymphadenopathy:

• Supraclavicular, cervical, axillary: Malignancy (lung cancer, metastases)
• Persistent generalized: TB, sarcoidosis, lymphoma

Cardiac Examination:

• Opening snap, diastolic murmur: Mitral stenosis
• S3 gallop, elevated JVP: Heart failure
• Loud P2, RV heave: Pulmonary hypertension

Skin and Extremities:

• Telangiectasias: Hereditary hemorrhagic telangiectasia (HHT) → pulmonary AVM
• Purpura, petechiae: Coagulopathy, vasculitis, thrombocytopenia
• Ecchymoses: Coagulation disorder, anticoagulation
• Cyanosis: Severe hypoxemia, AVM with shunting

Other Systems:

• Nasal/oral blood source: Rule out epistaxis (pseudohaemoptysis)
• Hematemesis features: Coffee-ground emesis, epigastric pain (upper GI bleed)
• Hematuria: Pulmonary-renal syndromes (GPA, Goodpasture, SLE)

Differentiating True Haemoptysis from Pseudohaemoptysis

Clinical Pearl: Up to 30% of patients with haemoptysis also report swallowing blood (from posterior pharyngeal drainage), which can then be vomited, confusing the presentation. Careful history about which came first (cough vs. vomit) is essential.

---

Red Flags

Life-Threatening Presentations (Immediate ICU + Intervention)

High-Risk Features for Adverse Outcomes

Patient Factors:

• Age > 70 years
• Significant comorbidities (COPD, heart failure, cirrhosis)
• Malignancy (especially squamous cell lung cancer)
• Immunosuppression (risk of fungal infection)
• On therapeutic anticoagulation

Clinical Features:

• Prior episode of massive haemoptysis
• Active tuberculosis (especially with cavitation)
• Known bronchiectasis or aspergilloma
• Bilateral lung disease on imaging
• Hemoglobin less than 7 g/dL at presentation

Radiographic Features:

• Aspergilloma (mycetoma)
• Cavitary lesion
• Vascular abnormality (AVM, aneurysm, Rasmussen)
• Extensive bilateral disease

Malignancy Red Flags (Urgent Outpatient Referral)

For patients with non-massive haemoptysis, the following features warrant urgent (2-week) cancer pathway referral:

• Age > 40 years with unexplained persistent haemoptysis
• Smoking history > 20 pack-years
• Unintentional weight loss > 5 kg in 6 months
• Persistent cough > 3 weeks
• Hoarseness (recurrent laryngeal nerve palsy)
• Lymphadenopathy (supraclavicular, cervical)
• Clubbing

---

Diagnostic Approach

Immediate Assessment (First 15 Minutes)

ABC Approach:

• A (Airway): Is it patent? Active bleeding visualized? Ability to clear secretions? Stridor or gurgling?
• B (Breathing): Respiratory rate, oxygen saturation, work of breathing, breath sounds (unilateral findings)
• C (Circulation): Blood pressure, heart rate, perfusion status, IV access

Quantify Severity:

• Estimate volume (recognizing inherent inaccuracy)
• Hemodynamic stability
• Respiratory compromise
• Classify as massive vs. non-massive using functional criteria

If Massive Haemoptysis:

1. Call for help: ICU, interventional radiology, thoracic surgery, anesthesia
2. Administer high-flow oxygen
3. Position bleeding-side down if known (or right lateral decubitus if unknown, as right mainstem bronchus larger)
4. Establish 2 large-bore IVs, type and crossmatch
5. Intubation decision (early is better than delayed in deteriorating patient)
6. Proceed to bronchoscopy for localization + intervention

Laboratory Studies

Imaging Studies

Chest X-Ray (PA and Lateral):

• First-line imaging for all patients with haemoptysis
• Sensitivity: 50-60% for localizing bleeding source [5]
• May be normal: 20-30% of haemoptysis, including up to 10% of malignancies

Positive Findings:

Limitations:

• Cannot differentiate bronchial vs. pulmonary artery source
• Poor visualization of vascular lesions
• Limited detail for bronchiectasis

CT Chest with IV Contrast (Gold Standard):

• Sensitivity: 70-80% for identifying bleeding source [5]
• Superior to CXR for parenchymal detail, vascular mapping, mediastinal evaluation

Indications:

• All patients with significant haemoptysis (> 20 mL)
• Normal CXR in patient with unexplained haemoptysis
• Pre-procedure planning for bronchoscopy or embolization

Findings:

• Bronchiectasis: Dilated airways (signet ring sign), bronchial wall thickening
• Malignancy: Mass, lymphadenopathy, metastases
• Vascular lesions: AVM, aneurysm, bronchial artery hypertrophy
• Infectious: Cavitation (TB), mycetoma (aspergilloma), abscess
• Pulmonary embolism: Filling defect (if CT pulmonary angiography protocol)
• Ground-glass opacities: Alveolar hemorrhage (DAH), invasive aspergillosis

High-Resolution CT (HRCT) Chest:

• Preferred for suspected bronchiectasis or interstitial lung disease
• Superior detail of small airways and lung parenchyma

CT Angiography (CTA) of Chest:

• Pre-embolization planning: Maps bronchial artery anatomy, identifies hypertrophied or anomalous vessels [7]
• Identifies vascular lesions: AVM, aneurysm, fistula
• Predicts non-bronchial systemic arterial supply: Internal mammary, subclavian, inferior phrenic arteries (seen in 20-30% of chronic lung disease) [7]

Indications:

• Planned bronchial artery embolization
• Suspected vascular malformation
• Massive haemoptysis of unclear source

Bronchoscopy

Flexible Bronchoscopy:

• Timing:
  • "Emergent: Massive haemoptysis with ongoing bleeding"
  • "Urgent (within 24h): Moderate haemoptysis, high-risk features"
  • "Elective: Non-massive haemoptysis for diagnosis"
• Diagnostic yield:
  • "During active bleeding: 90-95% localization success [2]"
  • "After bleeding stopped: 50-60% localization success"
• Advantages: Widely available, can be performed at bedside, enables biopsy and BAL
• Disadvantages: Limited suctioning capability, poor airway control in massive bleeding

Therapeutic Interventions via Flexible Bronchoscopy:

• Iced saline lavage (vasoconstriction)
• Topical epinephrine 1:20,000 (vasoconstriction)
• Balloon tamponade (Fogarty catheter)
• Application of topical hemostatic agents (oxidized cellulose, fibrin glue)
• Argon plasma coagulation (for visible endobronchial lesions)
• Electrocautery or laser photocoagulation

Rigid Bronchoscopy:

• Preferred for massive haemoptysis if available and expertise present [2]
• Advantages:
  • Superior airway control and ventilation
  • Large-bore suction (removes clots effectively)
  • Direct instrument insertion (forceps, cautery)
  • Rigid telescope provides excellent visualization
• Disadvantages: Requires general anesthesia, operator expertise, OR/endoscopy suite

Indications for Rigid Bronchoscopy:

• Massive haemoptysis with hemodynamic instability
• Failed flexible bronchoscopy
• Need for large clot removal
• Endobronchial tumor requiring debulking

Bronchial Artery Angiography

• Diagnostic and therapeutic: Identifies bleeding source and enables embolization
• Performed by interventional radiology
• Findings:
  • Bronchial artery hypertrophy (> 2 mm diameter, normal less than 1.5 mm)
  • Hypervascularity, tortuosity, aneurysms
  • Contrast extravasation (active bleeding, rare to visualize)
  • Non-bronchial systemic collaterals (seen in 20-30%) [7]
• Transition to therapy: Immediate embolization if bleeding source identified

Diagnostic Algorithm

Non-Massive Haemoptysis:

1. CXR → if abnormal, CT chest with contrast
2. If CXR normal: CT chest + outpatient bronchoscopy
3. Sputum studies (AFB × 3, cytology × 3)
4. Consider pulmonary function tests, CT angiography, autoimmune workup based on history

Massive Haemoptysis:

1. Immediate stabilization (ABC, IV access, positioning)
2. CXR at bedside (portable)
3. Bronchoscopy (localize source, temporize bleeding)
4. CT angiography (if hemodynamically stable, or after bronchoscopy)
5. Bronchial artery embolization (definitive therapy)
6. Thoracic surgery consultation (if embolization fails or not feasible)

---

Treatment

Principles of Management

1. Airway first: Protect from aspiration and asphyxiation
2. Lateralize bleeding: Position bleeding-side down to protect contralateral lung [2]
3. Resuscitation: Large-bore IV access, crystalloid, blood products as needed
4. Reverse coagulopathy: Stop anticoagulants, administer reversal agents
5. Localize source: Bronchoscopy + CT angiography
6. Control bleeding: Bronchoscopic intervention → bronchial artery embolization → surgery (stepwise escalation)
7. Treat underlying cause: Antibiotics for infection, anti-TB therapy, anticoagulation for PE, etc.

Airway Management

Positioning:

• Bleeding-side down (lateral decubitus position): Prevents contralateral aspiration [2]
• If laterality unknown: Right lateral decubitus (right mainstem bronchus is wider, less likely to obstruct)
• Sit upright if bilateral bleeding or unknown source
• Never supine in active massive haemoptysis

Intubation Indications:

• Inability to maintain oxygenation (SpO₂ less than 90% despite high-flow O₂)
• Inability to protect airway or clear secretions
• Altered mental status (GCS less than 8)
• Massive ongoing hemorrhage (> 100 mL/hour or rapid deterioration)
• Pre-procedural (before bronchoscopy in unstable patient)

Intubation Technique:

• Large-bore ETT (≥8.0 mm internal diameter): Allows passage of flexible bronchoscope through tube [1,2]
• Single-lumen ETT initially: Easier to place, enables bilateral suctioning
• Selective mainstem intubation: If bleeding side known, advance ETT into contralateral (non-bleeding) mainstem bronchus to isolate and protect
• Double-lumen endotracheal tube (DLT): Provides complete lung isolation, allows independent ventilation
  • "Indications: Unilateral massive bleeding, failed single-lumen ETT"
  • Requires anesthesia expertise
  • Facilitates unilateral PEEP to tamponade bleeding lung
• Bronchial blocker: Alternative to DLT, inserted alongside single-lumen ETT via bronchoscope to occlude bleeding bronchus

Post-Intubation Management:

• Positive end-expiratory pressure (PEEP 8-10 cm H₂O) may help tamponade bleeding
• Frequent suctioning to clear blood
• Bronchoscopy to localize and intervene

Resuscitation

Vascular Access and Fluids:

• 2 large-bore peripheral IVs (16-18 gauge)
• Central venous access if peripheral access inadequate (avoid subclavian approach given bleeding risk)
• Isotonic crystalloid (normal saline or lactated Ringer's) initially
• Avoid over-resuscitation (target SBP 90-100 mmHg) to prevent clot disruption

Blood Products:

• Type and crossmatch: 4-6 units PRBCs for massive haemoptysis
• Transfusion thresholds:
  • Hemoglobin less than 7 g/dL (restrictive strategy for stable patients)
  • Hemoglobin less than 9 g/dL for massive bleeding or hemodynamic instability
• Massive transfusion protocol if ongoing hemorrhage: 1:1:1 ratio (PRBCs:FFP:platelets)
• Platelets: Transfuse if less than 50,000/μL in active bleeding
• Fresh frozen plasma (FFP): If INR > 1.5-2.0, or empirically in massive transfusion
• Cryoprecipitate: If fibrinogen less than 150 mg/dL

Correction of Coagulopathy:

Pharmacological Treatments

Tranexamic Acid (Antifibrinolytic): [8,9]

• Mechanism: Inhibits plasminogen activation, stabilizes clot formation
• Evidence: Meta-analyses show reduced bleeding duration and volume in moderate-severe haemoptysis (Level I-II evidence) [8,9]
• Dosing:
  • "IV: 1 g IV over 10 minutes, then 1 g q8h"
  • "Nebulized: 500 mg (5 mL of 100 mg/mL solution) nebulized TID (investigational, growing evidence) [9]"
• Contraindications: Active thromboembolic disease, DIC, hematuria (genitourinary source)
• Adverse effects: Nausea, dizziness, theoretical thrombosis risk (low in short-term use)

Cold Saline Lavage (Bronchoscopic):

• Iced (4°C) normal saline in 10-20 mL aliquots via bronchoscope
• Mechanism: Local vasoconstriction, hypothermia-induced platelet activation
• Temporary effect (minutes)

Topical Epinephrine (Bronchoscopic):

• 1:20,000 dilution (5-10 mL aliquots) applied to bleeding site
• Mechanism: α-adrenergic vasoconstriction
• Temporary effect, useful for temporization during procedure

Vasopressin/Terlipressin:

• Investigational; some case reports suggest benefit
• Mechanism: Splanchnic vasoconstriction, reduced bronchial artery flow
• Not standard of care

Antibiotics:

• If pneumonia, lung abscess, or TB suspected
• Broad-spectrum empiric (e.g., piperacillin-tazobactam, ceftriaxone + metronidazole) until cultures available
• Anti-TB therapy if high suspicion (even before confirmation in endemic areas)

Bronchoscopic Interventions

Limitations:

• Bronchoscopic techniques are temporizing measures in massive haemoptysis
• Provide time to arrange definitive therapy (embolization or surgery)
• Recurrence common (30-50%) without definitive source control

Bronchial Artery Embolization (BAE)

First-Line Definitive Therapy for Massive Haemoptysis [6,7,10]

Indications:

• Massive or life-threatening haemoptysis not controlled by conservative measures
• Recurrent moderate haemoptysis (> 2-3 episodes)
• Patient not a surgical candidate (poor lung function, comorbidities)
• Localized bleeding source identified on angiography

Technique:

• Femoral artery access
• Selective catheterization of bronchial arteries (typically arising from descending aorta at T5-T6)
• Identification of abnormal vessels: hypertrophy (> 2 mm), tortuosity, hypervascularity, contrast extravasation
• Embolization using:
  • Polyvinyl alcohol (PVA) particles (preferred, 300-700 μm)
  • Gelfoam (temporary, resorbs in weeks)
  • Coils (for large vessels or aneurysms)
• Embolization of non-bronchial systemic collaterals if identified (internal mammary, subclavian, inferior phrenic)

Efficacy: [6,7,10]

• Immediate hemostasis: 85-95% success rate
• Recurrence rates:
  • "Early (less than 1 month): 10-30%"
  • "Late (> 1 month): 20-50% (highest in bronchiectasis, aspergilloma)"
• Predictors of recurrence:
  • Aspergilloma, active TB, malignancy
  • Incomplete embolization
  • Pulmonary artery source (not amenable to BAE)
  • Non-bronchial systemic artery bleeding

Complications: [7,10]

• Chest pain (most common, 20-40%): Usually self-limiting
• Dysphagia: Esophageal ischemia (5-10%)
• Spinal cord ischemia (most feared, 1-2%): Paraplegia from inadvertent anterior spinal artery embolization
  • Risk minimized by careful angiographic identification of spinal artery origin
  • Avoid embolization if spinal artery visualized
• Bronchial or esophageal necrosis (less than 1%)
• Contrast-induced nephropathy (5-10% in pre-existing renal impairment)
• Vascular access complications: Hematoma, dissection, pseudoaneurysm (less than 5%)

Post-Procedure:

• ICU monitoring for 24-48 hours
• Chest imaging to assess for complications
• Neurological examination (spinal cord ischemia surveillance)
• Treat underlying cause to prevent recurrence

Surgical Management

Indications:

• Failed bronchoscopy and embolization
• Localized disease amenable to resection (e.g., solitary aspergilloma, localized bronchiectasis)
• Massive haemoptysis from pulmonary artery source (e.g., Rasmussen aneurysm) not amenable to embolization
• Vascular malformation (AVM) with recurrent bleeding
• Trauma with persistent air leak or bleeding
• Tumor causing recurrent haemoptysis (palliative resection)

Procedures:

• Lobectomy: Most common, for localized disease
• Pneumonectomy: For extensive unilateral disease, higher morbidity/mortality
• Wedge resection: For peripheral lesions, AVMs
• Aneurysm ligation: For Rasmussen aneurysm or bronchial artery aneurysm

Outcomes: [11]

• Elective surgery (controlled bleeding): 5-10% mortality
• Emergency surgery (uncontrolled massive bleeding): 25-40% mortality
• Predictors of poor outcome:
  • Emergency setting
  • Pneumonectomy vs. lobectomy
  • Underlying malignancy
  • Poor baseline lung function (FEV₁ less than 40% predicted)

Surgery Reserved for Last Resort in acute massive haemoptysis due to high mortality; prefer BAE whenever possible.

---

Disposition

Admission Criteria

ICU Admission:

• Massive haemoptysis (any definition)
• Hemodynamic instability (SBP less than 90 mmHg, HR > 120 bpm)
• Respiratory failure or distress (SpO₂ less than 90%, RR > 30, need for intubation)
• Active ongoing bleeding (> 50 mL/hour)
• Post-embolization monitoring (first 24-48 hours)
• High-risk lesion (aspergilloma, malignancy, TB with cavitation)

General Ward Admission:

• Moderate haemoptysis (20-200 mL/day) with stable vitals
• Abnormal vital signs (tachycardia, tachypnea, fever)
• Significant underlying disease requiring inpatient workup (suspected malignancy, TB, pneumonia)
• Need for urgent bronchoscopy or intervention
• Anticoagulated patient with more than trivial bleeding
• Social factors precluding safe discharge (no support, cannot access emergency care)

Discharge Criteria (Outpatient Workup)

• Trivial haemoptysis (blood-streaked sputum, less than 20 mL)
• Stable vital signs, SpO₂ > 92% on room air
• No high-risk features (age less than 40, non-smoker, no weight loss, no mass on CXR)
• Able to arrange urgent outpatient follow-up (within 1-2 weeks)
• Reliable patient with access to emergency care
• No therapeutic anticoagulation (or held appropriately with specialist input)

Discharge Plan:

• Chest CT within 2 weeks
• Pulmonology referral (2-week cancer pathway if red flags present)
• Smoking cessation counseling and resources
• Written instructions on return precautions
• Stop NSAIDs, aspirin (unless essential for cardiovascular indication)

Follow-Up

---

Special Populations

Tuberculosis

Epidemiology:

• Leading cause of haemoptysis in developing countries (30-70% of cases) [3]
• Reactivation TB in apical fibrocavitary disease common source

Mechanisms:

• Active TB: Caseous necrosis, granulomatous inflammation, direct vessel erosion
• Rasmussen aneurysm: Mycobacterial invasion of pulmonary artery adjacent to cavity wall (10-15% of massive haemoptysis in TB) [3]
  • "Note: Pulmonary artery source, not bronchial artery; BAE less effective"
  • May require surgery or pulmonary artery embolization (higher risk)
• Post-TB bronchiectasis: Residual cavities with aspergilloma colonization
• Broncholith: Calcified lymph node eroding into airway

Management:

• Isolation: Airborne precautions, negative-pressure room
• Anti-TB therapy: Initiate empirically if high suspicion (rifampicin, isoniazid, pyrazinamide, ethambutol)
• Embolization: Less effective if pulmonary artery source
• Surgery: May be required for Rasmussen aneurysm or destroyed lung
• Public health: Notification, contact tracing, directly observed therapy (DOT)

Cystic Fibrosis and Bronchiectasis

Epidemiology:

• Haemoptysis occurs in 50-60% of CF patients during lifetime [13]
• Massive haemoptysis in 4-7% of CF patients

Mechanism:

• Chronic cycles of infection and inflammation
• Progressive bronchial artery hypertrophy and tortuosity
• Friable, fragile vessels prone to erosion during exacerbations

Management:

• Acute episode:
  • Stop airway clearance temporarily (risk of dislodging clot)
  • Hold inhaled mucolytics (DNase, hypertonic saline)
  • "Antibiotics for exacerbation (usually Pseudomonas coverage: piperacillin-tazobactam, ceftazidime, or tobramycin)"
  • Tranexamic acid (IV or nebulized) [9]
  • Bronchial artery embolization for massive or recurrent bleeding [13]
• Long-term:
  • Optimize pulmonary hygiene (airway clearance techniques between episodes)
  • Treat chronic infection (chronic suppressive antibiotics)
  • Consider lung transplantation evaluation if recurrent massive haemoptysis

Recurrence:

• Common (30-50%) due to ongoing inflammation and multiple hypertrophied vessels [13]
• May require repeat embolization

Malignancy

Epidemiology:

• Haemoptysis occurs in 20-50% of lung cancer patients during disease course [14]
• Squamous cell carcinoma most prone to bleeding (central, endobronchial location)

Mechanism:

• Tumor neovascularization with friable, immature vessels
• Direct invasion of bronchial arteries or pulmonary vessels
• Post-obstructive pneumonia
• Chemotherapy or radiation-induced necrosis

Management:

• Massive haemoptysis: Embolization first-line (surgery high risk in advanced disease)
• Palliative radiation: External beam radiotherapy can reduce bleeding (response in 60-80%) [14]
• Endobronchial interventions: Laser, electrocautery, cryotherapy, or brachytherapy for endobronchial tumors
• Palliative care: Discuss goals of care in advanced disease; dark towels and anxiolytics (benzodiazepines, opioids) for terminal hemorrhage

Prognosis:

• Massive haemoptysis in lung cancer portends poor prognosis (median survival 2-6 months)

Pulmonary Embolism

Epidemiology:

• Haemoptysis occurs in 20-30% of pulmonary embolism cases [15]
• Usually small volume (less than 50 mL)

Mechanism:

• Pulmonary infarction → alveolar hemorrhage
• Bleeding from low-pressure pulmonary circulation

Management:

• Anticoagulation is treatment (even though counterintuitive in bleeding): [15]
  • Prevents thrombus propagation
  • Bleeding from PE is usually self-limiting
  • Benefit of anticoagulation outweighs bleeding risk
  • Do not hold anticoagulation for minor-moderate haemoptysis due to PE
• Massive haemoptysis: Rare; consider IVC filter if recurrent PE despite therapeutic anticoagulation, or if anticoagulation contraindicated

Anticoagulated Patients

Risk:

• Higher risk of significant bleeding from underlying lesion
• Haemoptysis may unmask occult lung pathology (cancer, bronchiectasis)

Management:

• Trivial-mild bleeding: Often can continue anticoagulation if underlying indication strong (mechanical valve, recent VTE)
• Moderate bleeding: Hold anticoagulation temporarily, reverse if life-threatening, investigate underlying cause
• Massive bleeding: Reverse anticoagulation (see table above)
• Multidisciplinary discussion: Hematology, cardiology, pulmonology to weigh thrombosis risk vs. bleeding risk
• Bridging: Consider temporary IVC filter if high thrombosis risk and recurrent bleeding

Pregnancy

Differential Considerations:

• Physiologic increase in blood volume and vascularity
• Trophoblastic disease (choriocarcinoma) with pulmonary metastases
• Amniotic fluid embolism (rare, catastrophic)
• PE (higher risk in pregnancy)

Management:

• Avoid unnecessary radiation (shield abdomen, prefer MRI or limited CT if absolutely necessary)
• Bronchoscopy safe if indicated
• Multidisciplinary approach: pulmonology, obstetrics, anesthesia

---

Etiology-Specific Treatments

---

Prognosis

Overall Mortality

Prognostic Factors

Poor Prognosis:

• Underlying malignancy (median survival 2-6 months if massive haemoptysis)
• Aspergilloma (25-30% mortality if bleeding) [11]
• TB with Rasmussen aneurysm (50-80% mortality) [3]
• Failed embolization or surgery
• Bilateral lung disease
• Poor baseline lung function (FEV₁ less than 40% predicted)
• Age > 70 years, significant comorbidities

Good Prognosis:

• Idiopathic/cryptogenic haemoptysis (recurrence rare, mortality less than 1%)
• Bronchitis (self-limiting)
• Successful embolization with treatable underlying cause (e.g., pneumonia)

Recurrence Rates

After Bronchial Artery Embolization: [6,7,10]

• Overall recurrence: 10-30% (early) to 20-50% (late)
• Highest recurrence:
  • Aspergilloma (50-70%)
  • Active TB (40-50%)
  • Bronchiectasis (30-40%)
  • Malignancy (40-60%)
• Lowest recurrence:
  • Pneumonia, treated and resolved (less than 10%)
  • Idiopathic (less than 5%)

After Surgery:

• Recurrence less than 5% if complete resection of diseased lung
• Higher if residual diseased lung (e.g., incomplete resection in diffuse bronchiectasis)

---

Quality Metrics and Performance Indicators

Process Measures

Outcome Measures

Documentation Requirements

• Estimated volume of blood expectorated (even if approximate)
• Color and character of blood (bright red, dark, frothy, clots)
• Duration and frequency of bleeding episodes
• Initial CXR findings and lateralization if identified
• Lateralization assessment (patient perception, imaging, bronchoscopy)
• Oxygen requirements and vital signs trend
• Interventions performed (positioning, medications, bronchoscopy, embolization)
• Underlying etiology identified or suspected
• Disposition plan and follow-up arrangements

---

Key Clinical Pearls

Diagnostic Pearls

• Death is from asphyxiation, not exsanguination: As little as 150-200 mL of blood can fill the tracheobronchial tree and cause fatal hypoxia [1]
• Massive haemoptysis = life-threatening by function, not just volume: A patient with 50 mL of haemoptysis but SpO₂ 85% is "massive" and requires emergency intervention
• 90% of massive haemoptysis is from bronchial arteries: High-pressure systemic circulation; bronchial artery embolization is first-line [6,7]
• Normal CXR does not exclude serious pathology: 20-30% of haemoptysis has normal CXR, including up to 10% of lung cancers [5]
• Ask the patient which side they feel bleeding from: Correct in 60-70% of cases, guides positioning and management [2]
• Rule out pseudohaemoptysis: Epistaxis (posterior drainage) and hematemesis can mimic; ask about nausea/vomiting vs. coughing, check pH

Treatment Pearls

• Bleeding-side DOWN: Lateral decubitus position with bleeding lung dependent protects the "good" lung from aspiration [2]
• Large ETT for intubation (≥8.0 mm): Enables passage of flexible bronchoscope through ETT for diagnosis and therapy [1,2]
• Selective mainstem intubation: If unilateral bleeding and source known, advance ETT into contralateral (non-bleeding) mainstem to isolate
• Tranexamic acid may help: Level I-II evidence for reducing bleeding duration and volume; 1g IV q8h or 500 mg nebulized TID [8,9]
• Bronchial artery embolization is first-line for massive haemoptysis: 85-95% immediate success rate; surgery reserved for failures [6,7,10]
• Surgery is last resort in acute massive haemoptysis: 25-40% mortality in emergency setting vs. 5-10% elective [11]
• Anticoagulation for PE should NOT be held for minor-moderate haemoptysis: Benefit outweighs risk; bleeding from PE usually self-limiting [15]

Disposition Pearls

• All massive haemoptysis to ICU: Non-negotiable; require close monitoring, airway equipment, bronchoscopy/embolization capability
• TB isolation if cavity or risk factors: Airborne precautions even before microbiological confirmation
• Outpatient workup for trivial haemoptysis is acceptable: If age less than 40, non-smoker, no red flags, normal vitals, reliable patient; arrange CT chest within 2 weeks
• 2-week cancer pathway referral: Age > 40 with unexplained persistent haemoptysis, smoking history, or red flags [14]
• Smoking cessation is essential: Reduces recurrence risk and cancer risk; refer to cessation program at every encounter

Pitfalls to Avoid

• Delaying intubation in massive haemoptysis: "Too sick to intubate" is never true; earlier is safer than later
• Positioning patient supine during active bleeding: Risks bilateral aspiration and asphyxiation
• Over-resuscitation with IV fluids: May increase bleeding by raising blood pressure and disrupting clot
• Assuming volume-based definition of "massive": Functional classification (hemodynamic instability, respiratory compromise) is more clinically relevant
• Missing Rasmussen aneurysm in TB: Pulmonary artery source, not bronchial; BAE less effective, may require surgery
• Discharging patient with unexplained haemoptysis without CT imaging: Up to 10% of lung cancers present with haemoptysis and normal CXR
• Holding anticoagulation for minor haemoptysis in PE: Anticoagulation is the treatment, bleeding usually self-limiting

---

References

1. Davidson K, Shojaee S. Managing Massive Hemoptysis. Chest. 2020;157(1):77-88. doi:10.1016/j.chest.2019.07.012

2. Radchenko C, Alraiyes AH, Shojaee S. A systematic approach to the management of massive hemoptysis. J Thorac Dis. 2017;9(Suppl 10):S1069-S1086. doi:10.21037/jtd.2017.06.41

3. Abal AT, Nair PC, Cherian J. Haemoptysis: aetiology, evaluation and outcome - a prospective study in a third-world country. Respir Med. 2001;95(7):548-552. doi:10.1053/rmed.2001.1053

4. O'Gurek D, Choi HYJ. Hemoptysis: Evaluation and Management. Am Fam Physician. 2022;105(2):144-151. PMID:35166503

5. Cordovilla R, Bollo de Miguel E, Nuñez Ares A, et al. Diagnosis and Treatment of Hemoptysis. Arch Bronconeumol. 2016;52(7):368-377. doi:10.1016/j.arbres.2015.12.002

6. Yoon W, Kim JK, Kim YH, Chung TW, Kang HK. Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review. Radiographics. 2002;22(6):1395-1409. doi:10.1148/rg.226015180

7. Woo S, Yoon CJ, Chung JW, et al. Bronchial artery embolization to control hemoptysis: comparison of N-butyl-2-cyanoacrylate and polyvinyl alcohol particles. Radiology. 2013;269(2):594-602. doi:10.1148/radiol.13130046

8. Segrelles Calvo G, de Granda-Orive I, López Padilla D. Tranexamic acid for the treatment of hemoptysis. A systematic review of the literature. Arch Bronconeumol. 2019;55(10):529-536. doi:10.1016/j.arbres.2019.03.015

9. Ye M, Chen M, Wang C, et al. Nebulized Tranexamic Acid in the Management of Hemoptysis: An Integrative Review. Lung. 2025;203(1):28. doi:10.1007/s00408-024-00780-5

10. Sopko DR, Smith TP. Bronchial artery embolization for hemoptysis. Semin Intervent Radiol. 2011;28(1):48-62. doi:10.1055/s-0031-1273940

11. Andréjak C, Parrot A, Bazelly B, et al. Surgical lung resection for severe hemoptysis. Ann Thorac Surg. 2009;88(5):1556-1565. doi:10.1016/j.athoracsur.2009.06.078

12. Atchinson PRA, Hatton CJ, Roginski MA, et al. The emergency department evaluation and management of massive hemoptysis. Am J Emerg Med. 2021;50:148-155. doi:10.1016/j.ajem.2021.07.041

13. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808. doi:10.1164/rccm.200812-1845PP

14. Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest. 1997;112(2):440-444. doi:10.1378/chest.112.2.440

15. Stein PD, Terrin ML, Hales CA, et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest. 1991;100(3):598-603. doi:10.1378/chest.100.3.598

16. Fartoukh M, Khoshnood B, Parrot A, et al. Early prediction of in-hospital mortality of patients with hemoptysis: an approach to defining severe hemoptysis. Respiration. 2012;83(2):106-114. doi:10.1159/000331501

17. Rali P, Gandhi V, Tariq C. Massive Hemoptysis. Crit Care Nurs Q. 2016;39(2):139-147. doi:10.1097/CNQ.0000000000000107

18. Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med. 2000;28(5):1642-1647. doi:10.1097/00003246-200005000-00066

19. Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration. 2010;80(1):38-58. doi:10.1159/000274492

20. Lordan JL, Gascoigne A, Corris PA. The pulmonary physician in critical care: Assessment and management of massive haemoptysis. Thorax. 2003;58(9):814-819. doi:10.1136/thorax.58.9.814

21. Hafiz A, Baidwan A. "Massive" haemoptysis. Breathe (Sheff). 2025;21(3):250045. doi:10.1183/20734735.0045-2025

22. Sheppard M, Selvadurai H, Robinson PD, et al. Approaches to the management of haemoptysis in young people with cystic fibrosis. Paediatr Respir Rev. 2023;46:17-22. doi:10.1016/j.prrv.2022.10.002

---

Summary

Haemoptysis is a common and potentially life-threatening respiratory emergency requiring rapid assessment and intervention. The key principle is that massive haemoptysis kills by asphyxiation, not exsanguination, as small volumes of blood (150-200 mL) can completely occlude the tracheobronchial tree. Immediate priorities are airway protection, bleeding-side-down positioning, and resuscitation. Bronchial arteries (high-pressure systemic circulation) cause 90% of massive haemoptysis, making bronchial artery embolization the first-line definitive therapy with 85-95% immediate success. CT imaging and bronchoscopy localize the source. Etiology ranges from benign (bronchitis) to life-threatening (TB, cancer, aspergilloma). Tranexamic acid, bronchoscopic interventions, and early embolization improve outcomes, while surgery is reserved for failures or anatomically amenable cases. All massive haemoptysis requires ICU admission, and smoking cessation is essential for prevention of recurrence and underlying malignancy.